DE60236864D1 - Chimere alphavirus-replikon-partikel - Google Patents

Chimere alphavirus-replikon-partikel

Info

Publication number
DE60236864D1
DE60236864D1 DE60236864T DE60236864T DE60236864D1 DE 60236864 D1 DE60236864 D1 DE 60236864D1 DE 60236864 T DE60236864 T DE 60236864T DE 60236864 T DE60236864 T DE 60236864T DE 60236864 D1 DE60236864 D1 DE 60236864D1
Authority
DE
Germany
Prior art keywords
particles
alphavirus
replicant
alphaviruses
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60236864T
Other languages
English (en)
Inventor
John Polo
Sylvia Perri
Kent Thudium
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Application granted granted Critical
Publication of DE60236864D1 publication Critical patent/DE60236864D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/10—Vectors comprising a non-peptidic targeting moiety

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
DE60236864T 2001-05-31 2002-04-11 Chimere alphavirus-replikon-partikel Expired - Lifetime DE60236864D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29545101P 2001-05-31 2001-05-31
PCT/US2002/011585 WO2002099035A2 (en) 2001-05-31 2002-04-11 Chimeric alphavirus replicon particles

Publications (1)

Publication Number Publication Date
DE60236864D1 true DE60236864D1 (de) 2010-08-12

Family

ID=23137786

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60236864T Expired - Lifetime DE60236864D1 (de) 2001-05-31 2002-04-11 Chimere alphavirus-replikon-partikel

Country Status (9)

Country Link
US (2) US7531180B2 (de)
EP (3) EP1399183B1 (de)
JP (2) JP4608210B2 (de)
AT (1) ATE472335T1 (de)
AU (1) AU2002303330B2 (de)
CA (1) CA2448066A1 (de)
DE (1) DE60236864D1 (de)
ES (2) ES2624854T3 (de)
WO (1) WO2002099035A2 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
US20030232324A1 (en) * 2001-05-31 2003-12-18 Chiron Corporation Chimeric alphavirus replicon particles
DE50214200D1 (de) * 2001-06-05 2010-03-25 Curevac Gmbh Stabilisierte Tumorantigen-mRNA mit erhöhtem G/C-Gehalt
DE60233061D1 (de) * 2001-09-06 2009-09-03 Alphavax Inc Alphavirus replikon-vektorsysteme
DK1585812T3 (en) 2002-12-13 2017-04-10 Alphavax Inc MULTI-ANTI-ANTI-ANTI-VIRUS REPLICATE PARTICLES AND PROCEDURES
US7078218B2 (en) * 2002-12-13 2006-07-18 Alphavax, Inc. Alphavirus particles and methods for preparation
CA2518546C (en) * 2003-03-20 2012-11-13 Alphavax, Inc. Improved alphavirus replicons and helper constructs
BRPI0411099A (pt) * 2003-06-05 2006-07-18 Wyeth Corp composições imunogênicas que compreendem os vetores de replicon do vìrus da encefalite eqüina venezuelana e antìgenos de proteìnas de paramixovìrus
EP1651666B1 (de) * 2003-07-11 2009-05-27 Alphavax, Inc. Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
WO2005026316A2 (en) * 2003-09-15 2005-03-24 Bioption Ab Alphavirus vaccines
US7622125B2 (en) 2004-05-05 2009-11-24 Novartis Vaccines And Diagnostics, Inc. Polycistronic HIV vector constructs
ATE420965T1 (de) 2004-05-18 2009-01-15 Alphavax Inc Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren
EP1766034B1 (de) 2004-05-21 2014-03-19 Novartis Vaccines and Diagnostics, Inc. Alphavirus-vektoren für impfstoffe gegen das influenza virus
EP1773403B1 (de) 2004-07-09 2018-04-25 The University of North Carolina At Chapel Hill Auf alphavirus basierende adjuvanzien
EP2266602A3 (de) 2004-11-01 2011-08-10 Novartis Vaccines and Diagnostics, Inc. Kombinationswege zur Erzeugung von Immunantworten
US8486420B2 (en) 2005-02-15 2013-07-16 The University Of North Carolina At Chapel Hill Live virus vaccines
WO2007047749A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics Inc. Mucosal and systemic immunizations with alphavirus replicon particles
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
CA2636032C (en) * 2006-01-04 2016-04-12 Novartis Vaccines And Diagnostics, Inc. Activation of hcv-specific t cells
JP2010500399A (ja) 2006-08-16 2010-01-07 ノバルティス アーゲー 尿路病原性大腸菌由来の免疫原
WO2008115199A2 (en) * 2006-08-18 2008-09-25 The University Of North Carolina At Chapel Hill Chimeric virus vaccines
CN101802199B (zh) * 2007-06-21 2012-08-22 阿尔法瓦克斯公司 用于α病毒结构蛋白表达的无启动子盒
WO2009048633A2 (en) * 2007-10-11 2009-04-16 The Board Of Regents Of The University Of Texas System Chimeric chikungunya virus and uses thereof
AU2008314485B9 (en) 2007-10-15 2015-02-26 Jingang Medicine (Australia) Pty Ltd Expression system for modulating an immune response
US20110229969A1 (en) * 2008-06-25 2011-09-22 Volker Sandig Cell Line for Propagation of Highly Attenuated AlphaViruses
EP2310510B1 (de) * 2008-07-17 2015-05-06 Medigen, Inc. Idna-impfstoffe und verfahren zu ihrer verwendung
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
WO2011139717A1 (en) * 2010-04-26 2011-11-10 Novartis Ag Improved production of virus replicon particles in packaging cells
WO2014043518A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
EP2971188A1 (de) * 2013-03-15 2016-01-20 The U.S.A. as represented by the Secretary, Department of Health and Human Services Selektiver nachweis von hepatitis a-, b-, c-, d- oder e-viren oder kombinationen davon
US10172916B2 (en) 2013-11-15 2019-01-08 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating heart failure with agonists of hypocretin receptor 2
EP3189138A4 (de) 2014-09-07 2018-04-18 Selecta Biosciences, Inc. Verfahren und zusammensetzungen zur abschwächung der immunantworten auf antivirale geneditierende transfervektoren
EP3313863B1 (de) 2015-06-29 2020-12-23 The Board of Trustees of the Leland Stanford Junior University Degronfusionskonstrukte und verfahren zur steuerung der proteinproduktion
EP3331554B1 (de) 2015-08-03 2022-05-11 The U.S.A. as represented by the Secretary, Department of Health and Human Services Brachyury-deletionsmutanten, nichthefevektoren zur codierung von brachyury-deletionsmutanten und verwendung davon
US10596248B2 (en) 2015-12-09 2020-03-24 Jingang Medicine (Australia) Pty Ltd Immunomodulating composition for treatment
BR112018014109A2 (pt) 2016-01-11 2018-12-11 Verndari Inc composições de microagulhas e métodos de uso das mesmas
WO2017162265A1 (en) * 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
EP3565572A1 (de) 2017-01-07 2019-11-13 Selecta Biosciences, Inc. Strukturierte dosierung von an synthetische nanoträger gekoppelten immunsuppressiva
AU2018241252A1 (en) 2017-03-30 2019-10-03 The University Of Queensland Chimeric molecules and uses thereof
JP2020518648A (ja) 2017-05-08 2020-06-25 グリットストーン オンコロジー インコーポレイテッド アルファウイルス新生抗原ベクター
KR20200086670A (ko) 2017-10-13 2020-07-17 셀렉타 바이오사이언시즈, 인크. 항바이러스 전달 벡터 IgM 반응을 약화시키기 위한 방법 및 조성물
SG11202005618WA (en) 2017-12-19 2020-07-29 Akouos Inc Aav-mediated delivery of therapeutic antibodies to the inner ear
CN111818943A (zh) 2018-01-04 2020-10-23 伊科尼克治疗公司 抗组织因子抗体、抗体-药物缀合物及相关方法
JP2021515037A (ja) 2018-02-26 2021-06-17 アントルクス，インコーポレーテッド 寛容原性リポソーム及びその使用方法
MX2021004032A (es) * 2018-10-08 2021-07-06 Janssen Pharmaceuticals Inc Replicones basados en alfavirus para la administracion de bioterapeuticos.
US20200360453A1 (en) 2019-04-28 2020-11-19 Selecta Biosciences, Inc. Methods for treatment of subjects with preexisting immunity to viral transfer vectors
CA3141863A1 (en) 2019-05-28 2020-12-03 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
CA3140019A1 (en) 2019-05-30 2020-12-03 Gritstone Bio, Inc. Modified adenoviruses
WO2021021674A1 (en) 2019-07-26 2021-02-04 Akouos, Inc. Methods of treating hearing loss using a secreted target protein
KR20220129567A (ko) 2019-12-31 2022-09-23 엘릭서젠 쎄라퓨틱스, 인크. 핵산 및 단백질의 세포 및 조직으로의 온도-기반 일시적 전달
KR20230041965A (ko) 2020-05-13 2023-03-27 아카우오스, 인크. Slc26a4-연관 청력손실을 치료하기 위한 조성물 및 방법
TW202208406A (zh) 2020-05-13 2022-03-01 美商阿科奧斯公司 用於治療ｋｃｎｑ４相關性聽力損失之組成物及方法
WO2022032196A2 (en) 2020-08-06 2022-02-10 Gritstone Bio, Inc. Multiepitope vaccine cassettes
MX2023006451A (es) 2020-12-01 2023-06-15 Akouos Inc Construcciones de anticuerpos anti-vegf y metodos relacionados para el tratamiento de los sintomas asociados al schwannoma vestibular.
EP4271419A1 (de) 2020-12-29 2023-11-08 Akouos, Inc. Zusammensetzungen und verfahren zur behandlung von clrn1-assoziiertem hörverlust und/oder sehverlust
IL311572A (en) 2021-09-30 2024-05-01 Akouos Inc Compositions and methods for treating KCNQ4-related hearing loss
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023070072A1 (en) 2021-10-21 2023-04-27 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Retroelement-generated transcription factor decoys
CA3237482A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
TW202342525A (zh) 2022-02-02 2023-11-01 美商阿科奧斯公司 用於治療前庭神經鞘瘤相關症狀之抗ｖｅｇｆ抗體構築體及相關方法
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
WO2023183588A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Methods of assessing engineered retron activity, and uses thereof
WO2023183627A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna
WO2023183589A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Rt-dna fidelity and retron genome editing
WO2024009280A1 (en) 2022-07-08 2024-01-11 Baylor College Of Medicine Integrated stress response inhibitors and methods of using the same
WO2024020346A2 (en) 2022-07-18 2024-01-25 Renagade Therapeutics Management Inc. Gene editing components, systems, and methods of use
WO2024044673A1 (en) 2022-08-24 2024-02-29 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Dual cut retron editors for genomic insertions and deletions
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024086549A1 (en) * 2022-10-17 2024-04-25 The University Of North Carolina At Chapel Hill Chimeric alphaviruses for directed evolution

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4702909A (en) 1982-05-05 1987-10-27 Louisiana State University A & M Non-A, non-B hepatitis antigen, antigen compositions, vaccine and diagnostic reagent
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US5011915A (en) 1987-10-26 1991-04-30 Merck & Co., Inc. Process for purifying recombinant hepatitis antigens
EP0318216B2 (de) 1987-11-18 2001-08-29 Chiron Corporation NANBV-Diagnostika
US5698390A (en) 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
HUT54896A (en) 1989-03-17 1991-04-29 Chiron Corp Process for producing aquous diagnosticum and vaccine of nanbv
US6027729A (en) 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
GEP20002164B (en) 1989-05-18 2000-07-10 Novartis Vaccines & Diagnostic Oligomers, method for detecting of hcv sequence, kit for its detecting, method for production of the blood free from hcv
ES2106033T3 (es) 1989-05-19 1997-11-01 Genentech Inc Dominio extracelular de her2.
US5185440A (en) * 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
DK0444181T3 (da) 1989-08-04 2002-02-25 Schering Ag C-erbB-2 eksternt domæne: gp75
ATE152915T1 (de) 1991-11-29 1997-05-15 Viagene Inc Immuntherapeutische vektorkonstrukte gegen krebs
US6297048B1 (en) 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
CA2131729C (en) 1992-03-02 2008-02-12 Antonello Covacci Helicobacter pylori proteins useful for vaccines and diagnostics
US5869445A (en) 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
EP0694070B1 (de) * 1993-09-15 2002-04-10 Chiron Corporation Rekombinanter alphavirus vektor
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5778245A (en) * 1994-03-01 1998-07-07 Intel Corporation Method and apparatus for dynamic allocation of multiple buffers in a processor
ES2301178T3 (es) 1996-04-05 2008-06-16 Novartis Vaccines & Diagnostic Vectores basados en alfavirus recombinantes con inhibicion reducida de la sintesis macromolecular celular.
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
DE19630390A1 (de) 1996-07-26 1998-01-29 Chiron Behring Gmbh & Co Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung
US5842723A (en) 1996-11-25 1998-12-01 Burex Automotive America, Inc. Flexible connection arrangement for connecting a pipe of an exhaust system to an engine, especially in a motor vehicle
ATE297757T1 (de) 1997-02-28 2005-07-15 Acambis Inc Chimäre impfstoffe gegen flaviviren
US5935804A (en) 1997-03-21 1999-08-10 Laine; Roger A. Method for detecting eubacteria in biological samples with catalytically inactive murein binding enzymes
US6261570B1 (en) * 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
AU9363798A (en) 1997-11-06 1999-05-31 Chiron S.P.A. Neisserial antigens
CA2317815A1 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
GB9807721D0 (en) 1998-04-08 1998-06-10 Chiron Spa Antigen
ES2304065T3 (es) 1998-05-01 2008-09-01 Novartis Vaccines And Diagnostics, Inc. Antigenos y composiciones de neisseria meningitidis.
US6329201B1 (en) 1998-12-31 2001-12-11 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
AU2220800A (en) 1998-12-31 2000-07-31 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
CA2373300C (en) 1999-04-14 2012-02-21 Chiron Corporation Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
JP4658423B2 (ja) 1999-08-03 2011-03-23 ザ オハイオ ステイト ユニバーシティ Ｈｅｒ−２タンパク質に対する免疫反応性を増強するためのポリペプチドおよびポリヌクレオチド
WO2001081609A2 (en) 2000-03-22 2001-11-01 Chiron Corporation Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
US6865858B1 (en) 2000-04-27 2005-03-15 Marc T. Pollard Structural protection device and method of installing the same
CA2410948C (en) 2000-05-31 2012-07-17 Chiron Corporation Method for the purification of alphavirus replicon particles
CA2783274C (en) 2000-06-29 2018-08-07 Glaxosmithkline Biologicals S.A. Multivalent vaccine composition with reduced dose of haemophilus influenza type b
US20030232324A1 (en) * 2001-05-31 2003-12-18 Chiron Corporation Chimeric alphavirus replicon particles
EP2092916A1 (de) 2008-02-19 2009-08-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Verfahren zur Behandlung einer Augenkrankheit durch Verabreichung hochintensiven fokussierten Ultraschalls und entsprechende Vorrichtung
US9931272B2 (en) 2010-05-21 2018-04-03 Gregory Sadkhin Method for reducing a person's weight through hunger control
GB2530110A (en) 2014-11-03 2016-03-16 Multi Packaging Solutions Uk Ltd Packaging

Also Published As

Publication number Publication date
EP1399183A2 (de) 2004-03-24
JP4608210B2 (ja) 2011-01-12
US8158418B2 (en) 2012-04-17
WO2002099035A3 (en) 2003-12-18
JP2005515755A (ja) 2005-06-02
JP2010254711A (ja) 2010-11-11
CA2448066A1 (en) 2002-12-12
EP2332573A1 (de) 2011-06-15
EP2305299B1 (de) 2017-03-01
US20090305344A1 (en) 2009-12-10
EP1399183A4 (de) 2005-01-26
ATE472335T1 (de) 2010-07-15
AU2002303330B2 (en) 2008-07-24
US7531180B2 (en) 2009-05-12
ES2345876T3 (es) 2010-10-05
US20030148262A1 (en) 2003-08-07
ES2624854T3 (es) 2017-07-17
JP5268196B2 (ja) 2013-08-21
WO2002099035A2 (en) 2002-12-12
EP2305299A1 (de) 2011-04-06
EP1399183B1 (de) 2010-06-30

Similar Documents

Publication Publication Date Title
DE60236864D1 (de) Chimere alphavirus-replikon-partikel
AU2001275191A1 (en) Method for the purification of alphavirus replicon particles
WO2002059321A3 (en) Hepatitis c virus replicons and replicon enhanced cells
WO2003006616A3 (en) Pseudotyped adeno-associated viruses and uses thereof
NO20001768L (no) Viruskapsomervaksine, fremgangsmÕte til fremstilling samt anvendelse derav
HUP0301659A2 (hu) Kukorica cellulóz-szintetázok és alkalmazásuk
ATE500323T1 (de) Subtilisin-variante
NO20013701D0 (no) HER-2/neu-fusjonsproteiner
ATE270342T1 (de) Endosomolytisch wirksame partikel
WO2001021807A8 (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
DK1519944T3 (da) Fremgangsmåder til fremstilling af fibrinogen
ATE323166T1 (de) Fragmente der intron a von citomegalovirus
WO2000053776A3 (en) Human kallikrein-like genes
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
DE69928395D1 (de) Cyclin-e2 proteine und dafür kodierende gene
TW200508247A (en) Sars
WO2002027007A3 (en) Production of viral vectors
AU2003234342A1 (en) Ablated slam-dependent entry
AU2003258611A1 (en) Replicons of pestiviruses that do not express c and or e1 protein and infectious viral particles containing same, that can be used in vaccines
WO2002010417A3 (en) Methods and compositions for the construction and use of viral envelops as display particles
WO2004071462A3 (en) Methods and compositions for treatment of viral infections based on tsg101-vps28 interaction
WO2004048403A3 (en) Hepatisis c virus nonstructural protein 4a (ns4a) is an enhancer element
ATE263234T1 (de) Veränderte, kleine rna-viren
WO2002062964A3 (en) Ap1 amine oxidase variants
WO2002079222A3 (en) Fusion proteins for specific treatment of cancer and auto-immune diseases